Chris Boerner, Bristol Myers Squibb CEO
Unlike Merck, Bristol Myers to focus on bolt-ons after M&A spree
Bristol Myers Squibb likely won’t be on the hunt for big M&A targets in 2024 after pulling off a $14 billion deal for Karuna Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
